Apogee Therapeutics | LinkedIn (original) (raw)

About us

Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders.

Industry

Biotechnology Research

Company size

51-200 employees

Headquarters

Fully Remote, US

Type

Public Company

Founded

2022

Specialties

Immunology & Inflammation

Locations

Employees at Apogee Therapeutics

Updates

We are excited to announce we will host a virtual R&D Day on Monday, December 2, 2024 at 10am ET to highlight progress across our pipeline and showcase our path to reshaping the standard of care in I&I by bringing forward monotherapy and combination treatments that offer the potential for best-in-class efficacy and improved dosing.
We are thrilled to share that Apogee has earned a spot on the BioSpace 2025 #BestPlacetoWork list! At Apogee, we put people first. Our C.O.R.E. values of Caring, Original, Resilient and Egoless create an environment where team members thrive and make an impact for patients in need by developing potential new treatment options. Read more in the BioSpace 2025 Best Places to Work list. https://lnkd.in/gKuFq2cG
Today, we reported Q3 2024 financial results and updates from across our pipeline. We continue to execute across our portfolio and advance potentially transformative therapies for patients living with I&I diseases. Read through key updates below and learn more here. https://lnkd.in/e-J6ZUGH
16,555 followers
2w Edited
This month, members of our management team will participate in conferences hosted by Guggenheim, Stifel, and Jefferies. Learn more: https://lnkd.in/en9Z83pg
We are thrilled to congratulate Apogee CEO Michael Henderson on being named a Biocom California 2024 Life Science Catalyst Award winner! Michael's leadership and commitment to refusing to stop at good enough inspires us and plays a key role in our continued corporate growth and clinical progress. Congratulations, Michael!
We are thrilled to announce the winners of our ninth annual Life Science Catalyst Awards. The awards celebrate rising and accomplished academics, entrepreneurs, investors, corporate leaders and business advisers who are making significant contributions to the life science industry in California before reaching their 40th birthday. Biocom California selected the 10 winners from an impressive pool of nominees from all facets of the life science industry, including pharma, diagnostics, venture funding, industrial biotech and digital health. In alphabetical order, the Life Science Catalyst Award winners are: •Denise Bronner, Ph.D., founder and CEO, Empactful Ventures, LLC•Tyler Brown, Ph.D., founder, chair and president, OUTbio San Diego•Nick Goeden, Ph.D., co-founder and chief technology officer, Capsida Biotherapeutics•Michael Henderson, M.D., CEO, Apogee Therapeutics•Sophia Lugo, co-founder, chairman and CEO, Radar Therapeutics•Ana Moreno, Ph.D., founder and CEO, Navega Therapeutics•Nindhana Paranthaman, M.D., executive medical director of clinical development, Summit Therapeutics, Inc.•Kevin Parker, Ph.D., CEO and co-founder, Cartography Biosciences•Hunter Reed, vice president, Alexandria Venture Investments at Alexandria Real Estate Equities, Inc.•David Weinberg, Ph.D., co-founder and CEO, ParcelBioThe award winners will be highlighted in the Biocom California LifeLines digital platform and newsletter, on social media platforms and celebrated at our Annual Gala on November 21, 2024. Join us in congratulating this year’s award winners! See the winners here: https://bit.ly/3BLIGbt
Today, we announced results up to 9 months from the Phase 1 trial of APG777 for the treatment of #atopicdermatitis, building on positive interim data from the trial announced in March. These data continue to support a potential best-in-class PK and PD profile of APG777, and in particular, a near-complete inhibition of pSTAT6 and sustained TARC inhibition out to 9 months following a single dose. Read highlights from this data being presented at #ACAAI24 below, and find more in the press release here. https://lnkd.in/eKHjZXCR
Today, we announced an upcoming poster presentation of data up to 9 months from the ongoing Phase 1 clinical trial of APG777 at #ACAAI24. Find full details here. https://lnkd.in/eMVVD8tV
Beyond the physical manifestations of the condition, eczema can significantly decrease quality of life in a number of aspects. Despite available treatment options, there is a large unmet need for innovative, new treatment options for those living with eczema. This #EczemaAwarenessMonth and every month, Apogee is dedicated to never stopping at "good enough" and making an impact for patients in need.
Daily, intense itching. Red, inflamed skin lesions. Loss of sleep. Missing school, work and social events. This is #AtopicEczemaUnfiltered. The emotional and psychological effects of eczema are much deeper than what you see on the skin. On #WorldEczemaDay and every day, we are committed to working to improve the standard of care for conditions like eczema and refuse to stop at "good enough."

Join now to see what you are missing

Join now